Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 58

1.

High Kellgren-Lawrence Grade and Bone Marrow Lesions Predict Worsening Rates of Radiographic Joint Space Narrowing; The SEKOIA Study.

Edwards MH, Parsons C, Bruyère O, Petit Dop F, Chapurlat R, Roemer FW, Guermazi A, Zaim S, Genant H, Reginster JY, Dennison EM, Cooper C; SEKOIA Study Group.

J Rheumatol. 2016 Mar;43(3):657-65. doi: 10.3899/jrheum.150053. Epub 2016 Jan 15.

PMID:
26773120
2.
3.

Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials.

Karsdal MA, Byrjalsen I, Alexandersen P, Bihlet A, Andersen JR, Riis BJ, Bay-Jensen AC, Christiansen C; CSMC021C2301/2 investigators.

Osteoarthritis Cartilage. 2015 Apr;23(4):532-43. doi: 10.1016/j.joca.2014.12.019. Epub 2015 Jan 9.

4.

Osteoporosis in the European Union: a compendium of country-specific reports.

Svedbom A, Hernlund E, Ivergård M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, Kanis JA; EU Review Panel of IOF.

Arch Osteoporos. 2013;8:137. doi: 10.1007/s11657-013-0137-0. Epub 2013 Oct 11. Review.

5.

Is diabetes mellitus a heart disease equivalent in women? Results from an international study of postmenopausal women in the Raloxifene Use for the Heart (RUTH) Trial.

Daniels LB, Grady D, Mosca L, Collins P, Mitlak BH, Amewou-Atisso MG, Wenger NK, Barrett-Connor E; Raloxifene Use for the Heart (RUTH) Trial Investigators.

Circ Cardiovasc Qual Outcomes. 2013 Mar 1;6(2):164-70. doi: 10.1161/CIRCOUTCOMES.112.966986. Epub 2013 Mar 12.

6.

Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial.

Reginster JY, Badurski J, Bellamy N, Bensen W, Chapurlat R, Chevalier X, Christiansen C, Genant H, Navarro F, Nasonov E, Sambrook PN, Spector TD, Cooper C.

Ann Rheum Dis. 2013 Feb;72(2):179-86. doi: 10.1136/annrheumdis-2012-202231. Epub 2012 Nov 1.

7.

Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial.

Cooper C, Reginster JY, Chapurlat R, Christiansen C, Genant H, Bellamy N, Bensen W, Navarro F, Badurski J, Nasonov E, Chevalier X, Sambrook PN.

Curr Med Res Opin. 2012 Feb;28(2):231-9. doi: 10.1185/03007995.2011.648758. Epub 2012 Jan 17.

PMID:
22148897
8.

Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis.

Reginster JY, Kaufman JM, Goemaere S, Devogelaer JP, Benhamou CL, Felsenberg D, Diaz-Curiel M, Brandi ML, Badurski J, Wark J, Balogh A, Bruyère O, Roux C.

Osteoporos Int. 2012 Mar;23(3):1115-22. doi: 10.1007/s00198-011-1847-z. Epub 2011 Nov 29.

9.
10.

The application of FRAX® to determine intervention thresholds in osteoporosis treatment in Poland.

Badurski JE, Kanis JA, Johansson H, Dobreńko A, Nowak NA, Daniluk S, Jezienicka E.

Pol Arch Med Wewn. 2011 May;121(5):148-55.

11.

Once-yearly zoledronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial.

Cauley JA, Black D, Boonen S, Cummings SR, Mesenbrink P, Palermo L, Man Z, Hadji P, Reid IR; HORIZON Pivotal Fracture Group.

J Bone Miner Res. 2011 May;26(5):984-92. doi: 10.1002/jbmr.292.

12.

A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritis.

Cardiel MH, Tak PP, Bensen W, Burch FX, Forejtova S, Badurski JE, Kakkar T, Bevirt T, Ni L, McCroskery E, Jahreis A, Zack DJ.

Arthritis Res Ther. 2010;12(5):R192. doi: 10.1186/ar3163. Epub 2010 Oct 15.

13.
14.

Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate.

Gerlag DM, Hollis S, Layton M, Vencovský J, Szekanecz Z, Braddock M, Tak PP; ESCAPE Study Group.

Arthritis Rheum. 2010 Nov;62(11):3154-60. doi: 10.1002/art.27652.

15.

Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.

Eastell R, Lang T, Boonen S, Cummings S, Delmas PD, Cauley JA, Horowitz Z, Kerzberg E, Bianchi G, Kendler D, Leung P, Man Z, Mesenbrink P, Eriksen EF, Black DM; HORIZON Pivotal Fracture Trial.

Osteoporos Int. 2010 Jul;21(7):1277-85. doi: 10.1007/s00198-009-1077-9. Epub 2009 Oct 3.

16.

Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.

Eastell R, Black DM, Boonen S, Adami S, Felsenberg D, Lippuner K, Cummings SR, Delmas PD, Palermo L, Mesenbrink P, Cauley JA; HORIZON Pivotal Fracture Trial.

J Clin Endocrinol Metab. 2009 Sep;94(9):3215-25. doi: 10.1210/jc.2008-2765. Epub 2009 Jun 30.

17.

Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis.

Meunier PJ, Roux C, Ortolani S, Diaz-Curiel M, Compston J, Marquis P, Cormier C, Isaia G, Badurski J, Wark JD, Collette J, Reginster JY.

Osteoporos Int. 2009 Oct;20(10):1663-73. doi: 10.1007/s00198-008-0825-6. Epub 2009 Jan 20.

18.

The effects of tibolone in older postmenopausal women.

Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verweij P, Mol-Arts M, Kloosterboer L, Mosca L, Christiansen C, Bilezikian J, Kerzberg EM, Johnson S, Zanchetta J, Grobbee DE, Seifert W, Eastell R; LIFT Trial Investigators.

N Engl J Med. 2008 Aug 14;359(7):697-708. doi: 10.1056/NEJMoa0800743.

19.

Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate.

Bruyère O, Roux C, Badurski J, Isaia G, de Vernejoul MC, Cannata J, Ortolani S, Slosman D, Detilleux J, Reginster JY.

Curr Med Res Opin. 2007 Dec;23(12):3041-5.

PMID:
17967221
20.

Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis.

Marquis P, Roux C, de la Loge C, Diaz-Curiel M, Cormier C, Isaia G, Badurski J, Wark J, Meunier PJ.

Osteoporos Int. 2008 Apr;19(4):503-10. Epub 2007 Oct 11.

PMID:
17929073

Supplemental Content

Loading ...
Support Center